• DCVAX ® TECHNOLOGY
    • About DCVax®
    • Dendritic Cell Immunotherapy
  • PRODUCT CANDIDATES
    • DCVax® – L
    • DCVax® – Direct
    • DCVax® – Prostate
  • CLINICAL TRIALS
    • DCVax® – L Phase III for GBM Brain Cancer
    • DCVax® – Direct Phase I/II for All Types of Inoperable Solid Tumor Cancers
  • INVESTORS & MEDIA
    • Press Releases
    • SEC Filings
    • Webcasts
    • Board Committee Charters
    • Code of Conduct
    • Notice of Proposed Settlement
    • Related-Party Transaction Policy
    • Corporate Governance Guidelines
  • ABOUT US
    • Overview
    • Company Management
    • Publications
    • Related Links
    • Contact Us
      • New Patient Inquiry
      • General Inquiries

New Patient Inquiry

MM slash DD slash YYYY

(please leave Blank if not US)
(Enter 5-digit Zip Code if US)

Is this cancer newly diagnosed or recurrent?
What type of brain cancer?
MM slash DD slash YYYY

MM slash DD slash YYYY
(please leave Blank if not US)

(please leave Blank if not US)



Who should we reply to?

Follow us On: 
  • DCVAX® TECHNOLOGY
    • About DCVax®
    • Dendritic Cell Immunotherapy
    • Patient Stories & Physician Comments
  • PRODUCT CANDIDATES
    • DCVax® – L
    • DCVax® – Direct
    • DCVax® – Prostate
  • CLINICAL TRIALS
    • Pipeline
    • DCVax® – L Phase III
    • DCVax® – Direct Phase I/II
  • INVESTORS & MEDIA
    • Contacts
    • SEC Filings
    • Stock Information
    • Press Releases
    • Webcasts
  • ABOUT US
    • Overview
    • Company Management
    • Publications
    • Related Links
    • Contact Us

© 2017 Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800
Bethesda, MD 20814
Phone: 240-497-9024

  • Forward-looking Statement
  • Legal Disclaimer
  • Privacy Policy